Correlations between BCVA at baseline, month 12 and month 18 with the NEI-VFQ 25 composite score and scores of the two subscales of the MacTSQ at the corresponding times
| NEI-VFQ 25 composite baseline | MacTSQ subscale 1 Month 1 | MacTSQ subscale 2 Month 1 | |
| Baseline BCVA all eyes (N=110) | 0.387** | 0.009 | 0.153 |
| Baseline BCVA SE better eye (N=35) | 0.499** | 0.199 | 0.205 |
| Baseline BCVA SE worse eye (N=73) | 0.360** | 0.041 | 0.144 |
| NEI-VFQ 25 composite Month 12 | MacTSQ subscale 1 Month 12 | MacTSQ subscale 2 Month 12 | |
| Month 12 BCVA all eyes (N=100) | 0.329** | 0.065 | 0.027 |
| Month 12 BCVA SE better eye (N=30) | 0.496** | 0.200 | 0.173 |
| Month 12 BCVA SE worse eye (N=70) | 0.297* | 0.030 | 0.074 |
| NEI-VFQ 25 composite Month 18 | MacTSQ subscale 1 Month 18 | MacTSQ subscale 2 Month 18 | |
| Month 18 BCVA all eyes (N=98) | 0.405** | 0.144 | 0.000 |
| Month 18 BCVA SE better eye (N=31) | 0.548** | 0.058 | 0.104 |
| Month 18 BCVA SE worse eye (N=68) | 0.350** | 0.185 | 0.060 |
*Denotes significance at 0.01. Information provision and convenience and **Denotes significance at 0.001. Impact of treatment and satisfaction.
BCVA, best-corrected visual acuity; MacTSQ, Macular Disease Society Treatment Satisfaction Questionnaire; NEI-VFQ, National Eye Institute Visual Function Questionnaire; SE, study eye.